RT Journal Article
T1 Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP.
A1 Moriczi, Melinda
A1 Pujol-Muncunill, Gemma
A1 Martin-Masot, Rafael
A1 Jimenez Treviño, Santiago
A1 Segarra Canton, Oscar
A1 Ochoa Sangrador, Carlos
A1 Peña Quintana, Luis
A1 Gonzalez Santana, Daniel
A1 Rodriguez Martinez, Alejandro
A1 Rosell Camps, Antonio
A1 Armas, Honorio
A1 Barrio, Josefa
A1 Gonzalez de Caldas, Rafael
A1 Rodriguez Salas, Monica
A1 Balmaseda Serrano, Elena
A1 Donat Aliaga, Ester
A1 Bodas Pinedo, Andres
A1 Vaquero Sosa, Esther
A1 Vecino Lopez, Raquel
A1 Solar Boga, Alfonso
A1 Moreno Alvarez, Ana
A1 Sanchez Sanchez, Cesar
A1 Tolin Hernani, Mar
A1 Gutierrez Junquera, Carolina
A1 Martinon Torres, Nazareth
A1 Leis Trabazo, Maria Rosaura
A1 Eizaguirre, Francisco Javier
A1 Garcia Peris, Monica
A1 Medina Benitez, Enrique
A1 Fernandez Caamaño, Beatriz
A1 Vegas Alvarez, Ana Maria
A1 Crespo Valderrabano, Laura
A1 Alonso Vicente, Carmen
A1 Rubio Santiago, Javier
A1 Galera-Martinez, Rafael
A1 Garcia-Romero, Ruth
A1 Ros Arnal, Ignacio
A1 Fernandez Cebrian, Santiago
A1 Lorenzo Garrido, Helena
A1 Viada Bris, Javier Francisco
A1 Velasco Rodriguez-Belvis, Marta
A1 Bartolome Porro, Juan Manuel
A1 Blanco Rodriguez, Miriam
A1 Barros Garcia, Patricia
A1 Botija, Gonzalo
A1 Chicano Marin, Francisco Jose
A1 La Orden Izquierdo, Enrique
A1 Crehua-Gaudiza, Elena
A1 Navas-Lopez, Víctor Manuel
A1 Martin-de-Carpi, Javier
K1 Crohn’s disease
K1 calprotectin
K1 children
K1 exclusive enteral nutrition
K1 inflammatory bowel disease
K1 paediatric
AB Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014-2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6-8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn's Disease activity index [wPCDAI] 15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6-8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn's disease regardless of the location of disease and disease activity.
PB MDPI AG
YR 2020
FD 2020-04-03
LK http://hdl.handle.net/10668/15349
UL http://hdl.handle.net/10668/15349
LA en
NO Moriczi M, Pujol-Muncunill G, Martín-Masot R, Jiménez Treviño S, Segarra Cantón O, Ochoa Sangrador C, et al. Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP. Nutrients. 2020 Apr 7;12(4):1012.
DS RISalud
RD Apr 8, 2025